Attention on Cantargia in BioCentury

BioCentury The Bernstein Report on BioBusiness (Weekly), published on January 30, 2012 an Emerging Company Profile article on Cantargia; ““Cantargia: Stemming CML.”

BioCentury is internationally recognized as the leading provider of value-added information, analysis and data for biotechnology and pharmaceutical companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures.

Click on the link below to read the full BioCentury article on Cantargia.

013012_ECP_Cantargia.pdf